NCT07406659 Different Inspiratory Muscle Trainings in Patients With COPD
| NCT ID | NCT07406659 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Yalova |
| Condition | Chronic Obstructive Pulmonary Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 51 participants |
| Start Date | 2026-03-11 |
| Primary Completion | 2026-10-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 51 participants in total. It began in 2026-03-11 with a primary completion date of 2026-10-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
COPD is one of the most life-threatening pulmonary diseases. According to the World Health Organization, it is expected to rise to the third leading cause of death by 2030. Smoking is the most significant contributing factor. COPD reduces lung volumes and causes dyspnea. Over time, respiratory muscle weakness develops, leading to hypercapnia, dyspnea, nocturnal oxygen desaturation, and decreased exercise performance. Pulmonary rehabilitation is the most important component of COPD treatment. Respiratory muscle training should be a mandatory component of the pulmonary rehabilitation program. Combining inspiratory muscle training with functional exercises allows the focus to be on respiratory muscle functions beyond the task of breathing. The purpose of this study was to investigate the effects of Functional Inspiratory Muscle Training on the course of the disease.
Eligibility Criteria
Inclusion Criteria: Having a COPD diagnosis according to GOLD criteria Having not had an acute exacerbation within the last month Being able to walk independently Having no communication problems Voluntarily participating in the study Exclusion Criteria: Being in a COPD exacerbation Having an orthopedic or neurological disease that would prevent assessment and treatment Having uncontrolled hypertension and heart disease
Contact & Investigator
Erdi KAYABINAR, PhD
PRINCIPAL INVESTIGATOR
University of Yalova
Frequently Asked Questions
Who can join the NCT07406659 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Obstructive Pulmonary Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07406659 currently recruiting?
Yes, NCT07406659 is actively recruiting participants. Contact the research team at erdikayabinar@gmail.com for enrollment information.
Where is the NCT07406659 trial being conducted?
This trial is being conducted at Yalova, Turkey (Türkiye).
Who is sponsoring the NCT07406659 clinical trial?
NCT07406659 is sponsored by University of Yalova. The principal investigator is Erdi KAYABINAR, PhD at University of Yalova. The trial plans to enroll 51 participants.